INTRODUCTION
variety of new players some of whom will see a huge commercial opportunity and may push the boundaries of acceptability in terms of their claims. In addition, novel risks of harm to individuals may rise or be exacerbated by the new technologies. We therefore need to be assured that appropriate regulatory requirements are in place so that precision medicine can be undertaken efficiently and safely and in a manner that facilitates the translation of research into effective therapies.
Language that focuses attention on the 'person' immediately raises questions around personhood and privacy. As knowledge and understanding of personal health increases, so too do the potential threats to personal privacy. 'Medicine' implies that these new advances sit within the established medical care system, with all the regulatory checks and balances that go along with it. Yet, we will see in the discussion that follows that one of the features of precision medicine is the blurring of boundaries between the clinic, the laboratory, and the healthcare industry, creating new regulatory spaces. 4 On the one hand, this raises questions about the capacity of existing regulatory structures to respond. On the other hand, it risks regulatory overlap and confusion, a veritable 'regulatory soup' that could drown the promised advances in precision medicine.
Before we start to consider how precision medicine should be regulated, we need to be clear about what we mean by regulation. Here, the broad approach as Roger Brownsword and Morag Goodwin is adopted:
... we can treat 'regulation' as encompassing any instrument (legal or non-legal in its character, governmental or non-governmental in its source, direct or indirect in its operation, and so on) that is designed to channel group behaviour; and we can treat as a 'regulator' any person or body who initiates regulation in this broad sense. 5 In many ways, the regulatory challenges presented by precision medicine are reformulations of old tensions-community welfare versus individual liberty, risk versus benefit, autonomy versus paternalism. The potential for precision medicine to exacerbate existing disparities in health care, both within countries and internationally, should also be at the forefront of our concerns. 6 Here, we provide an overview of some of the more substantive issues that are likely to arise in responding to the perceived need to modernize the current regulatory landscape for precision medicine. The issues considered are largely based on discussions at the workshop, together with some of the more notable policy and academic commentaries. In the first part of this essay, we outline some of the major technological advances in the fields of precision medicine, including genome sequencing, pharmacogenomics, genomic analysis, gene editing, and biobanking. We go on to consider the regulatory landscapes within which these technologies are positioned with particular focus on what is needed to ensure that regulation is effective in the future.
Precision medicine r 285 THE PROMISE OF PRECISION MEDICINE Claims that precision medicine will deliver more personalized healthcare, tailored to an individual's genetic characteristics, health status and family history, are supported by several recent developments, particularly targeted therapies for the treatment of cancers. 7 Some commentators, however, are skeptical about the extent to which precision medicine research will, in the near future, be translated into genuine improvements in the delivery of healthcare. 8 Recognizing the need for dispassionate evaluation of the promise of precision medicine, there is, nevertheless, little doubt that it sits within a rapidly changing milieu, as illustrated in Fig. 1 .
During the past two decades, new technological developments such as massively parallel DNA sequencing have enabled high throughput analysis of DNA, RNA and proteins.
9 These developments have facilitated increased utilization of genetic and genomic information in the research context to provide valuable insights into the role of these factors in human health and wellbeing. This same genetic and genomic information is being used by clinicians in the delivery of healthcare, including assessing a person's predisposition to disease and assisting with their diagnosis and prognosis, as well as informing treatment decisions.
10 Whilst manufacture of new drugs has long been the province of pharmaceutical companies, the commercial sector is becoming increasingly involved in the delivery of healthcare, in particular diagnostic testing, once the exclusive purview of the medical profession.
Genome sequencing advances
Continuing advances in genome sequencing technology, together with massive reduction in costs, are together allowing multiple genetic variations to be assayed at the same time, often for the same cost as a single gene test.
11 Both whole exome sequencing (sequencing of the active components of human genes that code for proteins) and whole genome sequencing (WGS) are now feasible.
12 Given the possibility of extending testing well beyond the gene of interest indicated by clinical assessments, there has been some debate as to whether there is a duty of care to assess all known genetic alterations that may be present, in both the clinical and the research context. This era of more rapid genomic analysis has also witnessed the expansion of the for-profit private sector providing genomic services.
14 One of the leading sequencing companies, Illumina, is offering WGS to researchers and clinicians at rapidly reducing prices. For example, in 2011 it was offering whole tumor genome sequencing for around US$30,000.
15 By 2014, the company announced that its new sequencing technology gave it the capacity to offer WGS for US$1,000.
16 Although this figure does not factor in the significantly higher cost of bioinformatics analysis, ongoing improvements in high-performance computing and analytical algorithms will see this cost continue to decrease as well.
17
It is timely, at this stage, to reflect on how we might utilize the benefits resulting from increased accuracy and efficiency and reduced costs of sequencing in a way that benefits society as a whole. As Tim Caulfield and colleagues point out:
Rapid, lower-cost WGS is a promising research tool with unproven clinical utility, except in a small set of very specific situations. The journey from bench to bedside is one we should travel with care. ... The scale and pace of adoption of this powerful new technology should be driven by clinical need, clinical evidence, and a commitment to put patients at the centre of health care policy. 18 These salutary words illustrate that we should not be taken in by the hype that inevitably accompanies each new technological development. Rather, we should take a purposive approach, requiring clear evidence of safety and effectiveness, and, above all, focusing on patients' needs and interests.
Precision therapeutics-pharmacogenomics
The aim of pharmacogenomics is to combine targeted therapies with companion pretreatment diagnostic tests, which identify whether a person carries a gene or other biomarker that is linked with increased sensitivity to or resistance to the particular treatment. The starting point is improved understanding of how genetic variations within a population affect responses to particular drugs. 19 The most rapid advances have been in the field of molecular pathology and development of targeted cancer therapies. 20 Francis Collins and Harold Varmus, Directors of the US National Institutes of Health of the National Cancer Institute respectively, point out that the fact that cancers have their own heterogeneous genomic signatures opens avenues to the development of many more of targeted therapies. 21 But at the same time, this illustrates that the economic 
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costs of developing these bespoke treatments are likely to be enormous, requiring consideration of their value in meeting broader health system needs.
22
Although translation into the clinic has been slow, there are a few examples of combined diagnostic-therapeutic interventions that have been shown to confer significant benefits to individual patients in the field of oncology. 23 The most obvious example is the diagnostic test for the 'HER2' receptor in breast cancer tumors. Once diagnosed, HER2 positive tumors can be provided with therapeutic intervention using the anticancer drug trastuzumab (sold as Herceptin by Genentech). 24 The US Food and Drugs Administration (FDA), the administrator of the therapeutic goods registration scheme in that country, approved supply of Herceptin for therapeutic purposes in 1998. 25 Other molecular tests paired with appropriately targeted therapeutics are available for other cancer types including malignant melanoma, colorectal cancer, and several subtypes of leukemia and lymphoma. 26 Despite this, Collins and Varmus themselves acknowledge that many more cancer genomes will need to be analyzed and new designs of clinical trials and pre-clinical testing will need to be developed and approved to speed the adoption of precision therapies. 27 The emergence of drug resistance in cancer cells adds a further layer of complexity, perhaps requiring re-sequencing of some tumors. Whilst this experience in precision oncology is likely to expand into other spheres at some stage in the future, 28 broader adoption of precision medicine is still some way off. 29 Isaac Kohane identifies ten large challenges to be addressed for precision medicine to realize its potential. 30 Although he does acknowledge that these challenges are 'surmountable', their magnitude illustrates that we should be circumspect in our expectations about the immediacy of significant healthcare benefits arising from targeted therapies.
According to the FDA, the first challenge that must be overcome for precision medicine to advance is scientific. 31 Essentially, proof of analytic and clinical validity and clinical utility is required. However, the FDA also recognizes that regulatory policy and management challenges are posed by these technological advances. 32 Some commentators argue that current uncertainties in regulatory requirements are deterring investment in this field. This, they argue, is leading to the conclusion that there will need to be significant changes in the way that the FDA and equivalent agencies in other countries operate, along with 'unprecedented cooperation across multiple centers and 
Direct-to-consumer genomic analysis
Whilst the requirement for an appropriate quality control framework is recognized and becoming standardized within current health care settings, the regulatory space is becoming more complicated as private entities enter into the market providing direct-toconsumer genomic analysis. Genomic analysis of particular types of biomarkers, known as single nucleotide polymorphisms (SNPs), provides an estimate of an individual's risk of developing certain diseases or conditions relative to the rest of the population. 35 Companies like 23andMe, the leading US-based provider of genomic analysis using SNP arrays, offer the entirety of their analytical services directly to consumers (DTC), including reports on health risk factors. Other companies providing health-related analyses promote their services DTC but require that the test is ordered by, or the results returned to, healthcare providers. 36 In addition to health testing, companies offering DTC testing services often offer a range of other services such as ancestry inference 37 and sports-related genetic testing.
38 A large spectrum of other providers exist in the DTC space, at least some of which offer services of dubious value to consumers, adding further layers of complexity to the ethical, legal, and social landscape. 39 Notably, in late 2013, 23andMe ceased offering health related genomic analysis to consumers following receipt of a warning letter from the FDA requiring the company to show cause why it had not applied for marketing clearance or approval to supply this service. 40 Subsequently, in October 2015 23andMe launched a redesigned service, with authorization from the FDA, offering over sixty 'health, ancestry, wellness, and personal trait reports'. 
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Research advances-precision gene editing In parallel with these developments in sequencing, therapeutics and DTC genomic analysis, new trends have been emerging in the research context. Notably, there has been vast improvement in the accuracy of artificially manipulating genes, 42 particularly through Clustered Regularly Interspersed Short Tandem Repeat (CRISPR) and CRISPR associated (Cas) technology. Although still a research tool, CRISPR-Cas has been touted as having potential clinical application in the treatment of cancer and a range of other diseases. 43 For example, this technology can also be used in iPS cells (induced pluripotent stem cells), which are human cells (for example, skin fibroblasts) that are re-programmed so that they can differentiate into many different cell types. 44 This combination is opening up prospects for the development of gene therapies, particularly for blood-borne disorders but also other diseases. 45 Despite CRISPR-Cas's reported accuracy, however, there remain concerns that it could have off-target effects, potentially risking the activation of genes that trigger cancer formation.
46 Whilst advances are being made in identifying these effects, more comparative research is needed to understand how best to predict and minimize them. 47 These technological advances in gene editing have re-opened debates about the efficacy of therapeutic germline gene therapy 48 and deeper philosophical discussions around the manipulation of human embryos.
49
Biobanking and data sharing in a commercialized research environment Disease-specific and population biobanks have been established in many western countries to provide annotated collections of tissue, genomic data, and clinical information to researchers, through various combinations of public, charitable, and commercial funding. 50 The combined power of high throughput sequencing and electronic health records can now be harnessed to create opportunities to better understand genetic determinants of disease and health outcomes. 51 Together, they provide the essential resources and services for medical research into major diseases including cancer, cardiovascular disease, mental health disorders, and diabetes. seeing harmonization of biobank collections and coordination of research efforts internationally to increase the power of these rich bioresources and related infrastructure. 52 Whilst significant research advances have been made since the Human Genome Project commenced some 25 years ago, 53 much is still unknown about the implications of the multifaceted nature of gene and environment interactions on human health and wellbeing. We still have no clear understanding of the role of many genetic variants in human health and disease. 54 There is growing recognition of the value of data sharing in increasing our overall understanding of the human genome and facilitating the translation from early and later phases of research to clinical practice. 55 A range of organizations, including the International Cancer Genome Consortium, 56 the Global Alliance for Genomics and Health, 57 and projects like the Open Humans Network 58 have developed policies to promote the exchange of data. Data sharing does, however, become particularly complex for large-scale projects involving multiple players across jurisdictions and cultures. 59 Aside from public collections, pharmaceutical companies have maintained their own private collections of human biospecimens from clinical trials for many years, but these have largely been unavailable to external users. 60 In addition, some DTC companies, such as 23andMe, are using their databases to engage in research programs, both independently and in collaboration with biotechnology and pharmaceutical companies and public research organizations. 61 Even more recently, there has been an indication that 23andMe is launching itself into the drug discovery environment.
62
These developments are raising questions about how to provide appropriate oversight of research in light of the collapsing of traditional boundaries between: the research institution and the clinic; the patient, the research participant, and the consumer; the public and commercial research sectors; and the diagnostic and therapeutic sectors. Patients, research participants, and consumers are also increasingly expected to be active participants in precision medicine rather than passive subjects or recipients of its benefits (and arguably increasingly burdened with expectations of engagement). 
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Precision medicine heightens many of the concerns about ethical, legal, and social implications (ELSI) raised during the course of the Human Genome Project and beyond. 64 The linkage of genotype and phenotype, past medical history, lifestyle, and other personal information, raises particular concerns around consent, privacy, and confidentiality, together with obvious practical questions about the accuracy, safety, and clinical validity of the therapeutic products. These and other ELSI come into sharp focus as precision medicine advances, with the proliferation in the amount of information potentially available, the scale of linkage, and the untested nature of many of the claimed therapeutic outcomes.
65

DROWNING IN THE REGUL ATORY SOUP?
Regulating across areas of emerging or rapidly developing technologies with evolving industry structures will always present unique challenges. 66 Regulation must be responsive to technological developments and as future-proofed as possible, if it is to have a chance of 'leading'. In a world of increasingly porous borders and increased participation in the borderless online world, regulation must be accommodating of differing cultural norms, not just within, but amongst individual countries or regions.
67 This is a tall order for any regulator when the landscape and the key participants keep changing.
These regulatory challenges need not-and probably should not-result in new, highly targeted laws, which are liable to be outpaced by scientific change. Instead, and to the greatest extent possible, precision medicine should be regulated by the large body of existing laws and other regulatory instruments that apply to other aspects of clinical care and medical research. Nor should it be used as a justification for recalibration of high-level ethical principles such as those contained within the Declaration of Helsinki, with the potential of undermining the current authority of those principles.
68 Whilst precision medicine might be scientifically new, it exists within these well-established regulatory and oversight systems.
Some of the most relevant broadly-based regulatory and legal requirements include: consumer protection legislation designed to ensure product safety and prevent false or misleading marketing; privacy legislation that protects personal medical information; and established duties of care and consent requirements with remedies for breaches (for example, the torts of trespass and negligence). There are also a number of specifically designed regulatory regimes relating to drug approvals, diagnostic testing, and research. Their adequacy and appropriateness with regard to some of the key features of precision medicine is discussed further below.
Specific regulatory challenges for pharmacogenomics
Pharmacogenomics is positioned within the regulatory and oversight system for market approval of therapeutic goods. The current model for regulating drug approvals clearly has inadequacies in this space because the evidence upon which decisions are made 64 Chalmers et al., supra note 7, at 578; Brothers and Rothstein, supra note 6, at 43. 
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comes from large randomized clinical trials. 69 The system is simply not designed with personalized treatments in mind. 70 In response to these and other pressures, governments in a number of jurisdictions are examining reform options from both the regulatory perspective (for example, through adaptive licensing) and the funding perspective (including performance-based risk sharing agreements). 71 Concerns have been raised as to whether these proposed reforms can be implemented successfully, with commentators urging that they should be 'approached with a healthy degree of skepticism'. 72 Other commentators posit that what is needed is a new approach of hypothesistesting clinical trials, arguing that analytical validation of biomarker assays will be a key component. 73 In this regard, note should be taken of the work of the International Conference on Harmonization, which is attempting to formulate mutually agreed biomarker qualification standards between the European Union, USA, and Japan. 74 The FDA itself has recognized that one of the significant challenges in approvals for targeted therapies and companion diagnostics is that the products are regulated by different FDA Centers and often sponsored by different companies. 75 The FDA has taken some modest steps in response, but recognizes that more will need to be done.
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Regulating direct-to-consumer genomic analysis Genetic diagnostic testing is subject to a range of specific regulatory instruments. For instance, the US-based genetic diagnostic testing sector is subject to laboratory accreditation at the state level and through the Centers of Medicare and Medicaid Services, as well as market clearance and approval for in vitro devices (IVDs) through the FDA. Other jurisdictions have similar regulatory requirements. 77 As precision medicine moves further into a world of DTC delivery, consumers can increasingly bypass traditional healthcare systems and healthcare providers in favor of these commercial offerings. 78 While existing consumer protection regulatory frameworks may already adequately cover products made directly available to consumers, they do not necessarily provide the same level of protection in relation to DTC services. 79 Concerns have long been expressed about the accuracy of the predictions made by DTC testing companies, 80 and consumer ability to understand and interpret test results, particularly in an environment where there is typically no genetic counseling. 81 It should be noted, however, that a robust evidence base of documented harms is still lacking. 82 Moreover, the nature of some of these harms is contestable, with some commentators arguing that adults, as healthcare consumers, should have the freedom to choose whether or not to access these services, and indeed that they have the right to access and possess their health data.
83
One recent extension of regulatory oversight has been to include laboratorydeveloped tests (LDTs) within the IVD regulatory framework. 84 In the USA, the FDA is still in the process of developing this framework for oversight of LDTs, and once further developed may face legal challenge.
85
Regulating the evolving research space Publicly funded researchers and public research institutions are bound by national codes of research ethics; and in the clinic, health care practitioners are bound by professional and ethical codes of conduct. These 'soft' laws can provide more nuanced assistance in guiding ethical conduct than blunt legislative intervention. But it is perhaps in these areas that the regulatory puzzle is most perplexing. In the era of precision medicine, where the traditional boundaries around public research and professional care are being transcended, 86 can these soft laws be adapted to suit this new environment? There is a risk that these soft laws could actually create more layers of regulatory complexity and confusion in this multidisciplinary area, given that different professions have different codes of conduct, and that a substantial body of hard laws is already in existence. Thus, achieving regulatory consistency in this cross-disciplinary, cross-jurisdictional space, positioned between the public and private sectors, will be challenging.
National ethical research codes, which put the responsibilities associated with approval and compliance on institutions, are not a good fit for collaborative research that crosses institutional and disciplinary boundaries because research teams inevitably face review by a multitude of institutional research ethics committees (referred to as Institutional Review Boards in the US). This problem has already been recognized by the US Department of Human and Health Services (DHHS) 
Other regulatory tools
Research funding, health care reimbursement schedules, and insurance coverage must be recognized as key components of the regulatory framework. Although perhaps not traditionally thought of as regulatory instruments as such, each of these is relevant because it has the capacity to channel group behavior, thereby coming within Brownsword and Goodwin's definition of regulation. Regulatory theorists have long accepted that there is more to regulation than laws and other regulatory instruments.
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For instance, reimbursement will only be provided for new genetic tests if there is clear evidence of analytical validity, clinical validity, and clinical utility. 118 Essentially, in such circumstances, reimbursers become de facto regulators, fulfilling like functions.
119
Other legal regimes, including the patent system, also have a regulatory function in this space, particularly with respect to diagnostic testing. Perhaps inadvertently, recent decisions of the US Supreme Court and the Australian High Court redefining the legal requirements for patentable subject matter 120 may have the effect of increasing the regulatory burden on the FDA and others. The reason for this suggestion is that removal of the threat of patent infringement will likely open up the diagnostic testing market to new entrants. In the past, the grant of patents claiming rights to nucleotide sequences and associated diagnostic methods created de facto barriers to entry into the genetic diagnostic testing market, either through actual instances of patent enforcement, or fears from diagnostic testing laboratories that they at any time could face patent infringement lawsuits. As noted in the recent Report on Confirmatory Genetic Diagnostic Test Activity by the US Patent and Trademarks Office, these cases have 'dramatically affect[ed] the landscape of diagnostic testing'. 121 Although the Report focuses specifically on confirmatory (or second opinion) tests, it illustrates the point that the gatekeeping role of gene-based patents has been largely extinguished. The Report concludes that this changing landscape will result in many smaller providers entering the market. 122 This will be beneficial to consumers, if it increases choice and decreases cost, but may increase the burden on regulators in ensuring regulatory compliance as the number of providers expands. Moreover, the gatekeeper role could shift to the insurer to make choices around such questions as which tests from which laboratories should be eligible for reimbursement. However, to date only the US and Australian courts have ruled on the ineligibility of nucleotide sequence patents based on the subject matter ground. In Europe, provisions in the European Biotechnology Directive (particularly Article 5) subject matter ground to be brought in countries that have implemented the Directive into their domestic patent legislation.
It is also pertinent that other intellectual property regimes are already taking the place of patents in regulating entry of alternative providers into the diagnostic testing market. Companies that have been offering diagnostic tests exclusively for a number of years in reliance on their patent rights, now have extensive databases of populationwide genetic data, which are used to compare genetic variations of otherwise unknown significance with particular disease manifestations. 124 Trade secrecy laws allow them to keep their data confidential. Circumventing this proprietary database dilemma will require creation of an equivalent public access dataset. 125 This will take time, and in the interim private companies will still exert a powerful influence in regulating market entry of other providers. Figure 1 illustrated how the traditional boundaries between the clinic, the research lab and the different industry sectors are breaking down. One consequence is that the defined regulatory spaces within which each of these sectors operate become a diffuse regulatory soup, as illustrated in Fig. 2 .
The regulatory soup
The first task in responding to President Obama's call to modernize the current regulatory landscape is not so much about adding further ingredients to this regulatory soup, but working out how to engage with, interpret and, where necessary, expand existing ingredients in new areas of technology. Equally important, this task will require us to work out how to avoid overlap and duplication. Relevant questions to consider when assessing the reach of regulation include (but are not limited to): what are the regulatory requirements for approval of targeted therapies that provide an appropriate balance between incentivizing innovation and ensuring that clinical validity and patient safety requirements are satisfied; 126 should DTC companies that provide risk reports based on SNP analysis be regulated in the same way as more conventional providers of genetic diagnostic services; and how should genomic research be regulated, in light of these collapsing boundaries?
THE REGUL ATORY FUTURE− CAN REGUL ATION BE EFFECTIVE?
As noted by Collins and Varmus, the regulatory challenge is to find a way of supporting innovation and ensuring that the technology is safe and effective, and also cost effective. 127 While there is a tendency to criticize the law for 'limping behind' technology, best practice regulation can only be achieved if it is informed by an appropriate evidence base, with adequate opportunities for reflection and debate. The sector needs to remain adaptive, flexible and responsive to change and new research and clinical opportunities. Caution is required in law reform relating to precision medicine, lest we fall victim to genetic exceptionalism, which might introduce more problems than it resolves. 
